TRAIL and its receptors as targets for cancer therapy

被引：215

作者：

Yagita, H

Takeda, K

Hayakawa, Y

Smyth, MJ

Okumura, K

机构：

[1] Juntendo Univ, Sch Med, Dept Immunol, Bunkyo Ku, Tokyo 1138421, Japan

[2] Peter MacCallum Canc Ctr, Canc Immunol Program, Melbourne, Vic 3002, Australia

来源：

CANCER SCIENCE | 2004年 / 95卷 / 10期

关键词：

D O I：

10.1111/j.1349-7006.2004.tb02181.x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF family of cytokines, which can induce apoptotic cell death in a variety of tumor cells by engaging the death receptors DR4 and DR5, while sparing most normal cells. Preclinical studies in mice and non-human primates have shown the potential utility of recombinant soluble TRAIL and agonistic anti-DR5 or DR4 antibodies for cancer therapy. Moreover, we have recently revealed a vital role for endogenously expressed TRAIL in immunosurveillance of developing and metastatic tumors. In this review, we summarize recent knowledge about TRAIL and its receptors as promising targets for cancer therapy.

引用

收藏

页码：777 / 783

页数：7

相关论文

共 68 条

[1] Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL [J].

Altucci, L ;

Rossin, A ;

Raffelsberger, W ;

Reitmair, A ;

Chomienne, C ;

Gronemeyer, H .

NATURE MEDICINE, 2001, 7 (06) :680-686

[2]

Armeanu S, 2003, CANCER RES, V63, P2369

[3] Safety and antitumor activity of recombinant soluble Apo2 ligand [J].

Ashkenazi, A ;

Pai, RC ;

Fong, S ;

Leung, S ;

Lawrence, DA ;

Masters, SA ;

Blackie, C ;

Chang, L ;

McMurtrey, AE ;

Hebert, A ;

DeForge, L ;

Koumenis, IL ;

Lewis, D ;

Harris, L ;

Bussiere, J ;

Koeppen, H ;

Shahrokh, Z ;

Schwall, RH .

JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162

[4] Targeting death and decoy receptors of the tumour-necrosis factor superfamily [J].

Ashkenazi, A .

NATURE REVIEWS CANCER, 2002, 2 (06) :420-430

[5] Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced in multiple myeloma [J].

Chen, Q ;

Gong, B ;

Mahmoud-Ahmed, AS ;

Zhou, A ;

Hsi, ED ;

Hussein, M ;

Almasan, A .

BLOOD, 2001, 98 (07) :2183-2192

[6] Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy [J].

Chinnaiyan, AM ;

Prasad, U ;

Shankar, S ;

Hamstra, DA ;

Shanaiah, M ;

Chenevert, TL ;

Ross, BD ;

Rehemtulla, A .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (04) :1754-1759

[7] Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4 [J].

Chuntharapai, A ;

Dodge, K ;

Grimmer, K ;

Schroeder, K ;

Marsters, SA ;

Koeppen, H ;

Ashkenazi, A ;

Kim, KJ .

JOURNAL OF IMMUNOLOGY, 2001, 166 (08) :4891-4898

[8] Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice [J].

Cretney, E ;

Takeda, K ;

Yagita, H ;

Glaccum, M ;

Peschon, JJ ;

Smyth, MJ .

JOURNAL OF IMMUNOLOGY, 2002, 168 (03) :1356-1361

[9] To die or not to die - the quest of the TRAIL receptors [J].

Degli-Esposti, M .

JOURNAL OF LEUKOCYTE BIOLOGY, 1999, 65 (05) :535-542

[10] Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) [J].

Fanger, NA ;

Maliszewski, CR ;

Schooley, K ;

Griffith, TS .

JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (08) :1155-1164

← 1 2 3 4 5 6 7 →